Citadel Advisors
RLMD icon

Citadel Advisors’s Relmada Therapeutics RLMD Stock Holding History

Citadel Advisors’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,700
Closed -$56.5K – 14039
2025
Q4 		$56.5K Buy
+11,700
New +$39.2K ﹤0.01% 11975
2025
Q1 		– Sell
-46,500
Closed -$24.2K – 15406
2024
Q4 		$24.2K Sell
46,500
-4,100
-8% -$10K ﹤0.01% 13050
2024
Q3 		$164K Buy
50,600
+22,400
+79% +$72.5K ﹤0.01% 10448
2024
Q2 		$84.6K Sell
28,200
-31,100
-52% -$113K ﹤0.01% 11143
2024
Q1 		$276K Sell
59,300
-19,000
-24% -$91.6K ﹤0.01% 9645
2023
Q4 		$324K Buy
78,300
+25,200
+47% +$74.6K ﹤0.01% 9018
2023
Q3 		$159K Sell
53,100
-23,800
-31% -$70.7K ﹤0.01% 10260
2023
Q2 		$189K Buy
76,900
+44,300
+136% +$122K ﹤0.01% 9985
2023
Q1 		$73.7K Sell
32,600
-62,900
-66% -$217K ﹤0.01% 11663
2022
Q4 		$333K Sell
95,500
-389,800
-80% -$3.42M ﹤0.01% 9082
2022
Q3 		$18M Buy
485,300
+360,300
+288% +$9.98M ﹤0.01% 1997
2022
Q2 		$2.37M Buy
125,000
+84,800
+211% +$1.85M ﹤0.01% 5216
2022
Q1 		$1.08M Buy
40,200
+28,900
+256% +$598K ﹤0.01% 7509
2021
Q4 		$255K Sell
11,300
-5,300
-32% -$118K ﹤0.01% 11302
2021
Q3 		$435K Sell
16,600
-1,700
-9% -$45.5K ﹤0.01% 10222
2021
Q2 		$586K Buy
18,300
+5,100
+39% +$177K ﹤0.01% 9687
2021
Q1 		$465K Buy
+13,200
New +$462K ﹤0.01% 9831

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Citadel Advisors's RLMD Position: Q1 2026 in Review

Citadel Advisors sold out of Relmada Therapeutics (RLMD) in Q1 2026, closing a stake of 28,063 shares — an estimated $133K sold.

Citadel Advisors first reported a position in RLMD in Q4 2019 and held it in 19 quarters. The position peaked at $34.5M in Q3 2022. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • Citadel Advisors reported no remaining Relmada Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 28,063 Relmada Therapeutics shares in Q1 2026, an estimated $133K.
  • Citadel Advisors first reported a position in Relmada Therapeutics in Q4 2019 and held it in 19 quarters.
  • Citadel Advisors's Relmada Therapeutics position peaked at $34.5M in Q3 2022.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.